CD47 and hematologic disorder: Given that radiotherapy is a common treatment option for patients with SCLC and that several clinical trials to test anti-CD47 antibody efficacy against hematologic malignancies and solid tumors are ongoing51–54, our preclinical findings could be readily tested in the clinic in patients with SCLC and other cancers.